Breaking News

Financial Report: Hospira

February 13, 2013

Specialty Injectable sales up 12% in the quarter

Hospira

4Q Revenues: $1.1 billion (+8%)

4Q Earnings: $5.3 million (loss of $214 million 4Q11)

FY Revenues: $4.1 billion (+1%)

FY Earnings: $44.2 million (loss of $9.4 million FY11)

Comments: Growth in the quarter was driven strong sales of Specialty Injectable Pharmaceutical (SIP) products, up 12% to $696 million, including Precedex globally and oncolytic oxaliplatin in the U.S., as well as higher volumes for certain products in the EMEA region. SIP sales in the Americas were  $539.6 million, up 13%; EMEA sales were $83.3 million, up 14%; APAC sales were flat at $73.3 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks